All Posts

In the world of global health, numbers often tell the story before the symptoms do. Today, approximately 200 million people  worldwide are living with Age-Related Macular Degeneration (AMD). By 2040, that number is projected to reach 288 million . But the most critical statistic isn't the total prevalence; it is the disparity in care. 85–90%  of these patients have the "dry" form of the disease. Yet, for decades, the vast majority of therapeutic innovation has focused on the

In the rapidly evolving landscape of health technology, there is a distinct line between consumer "wellness gadgets" and regulated medical devices. At BioPhotonix, we have chosen our side of that line with absolute clarity. We are not building a lifestyle accessory; we are engineering a Class IIa medical device  intended to treat a progressive retinal disease. This distinction drives every decision we make, from the materials we select to the regulatory frameworks we follow.

For decades, the standard of care for early and intermediate dry Age-Related Macular Degeneration (AMD) has been defined by a single, frustrating limitation: the gap between diagnosis and treatment. As an optometrist and orthoptist working on the front lines of eye care, I witnessed this narrative repeat itself daily. Patients would arrive for routine appointments, only to be diagnosed with a progressive condition that threatens their central vision and independence. But the

At BioPhotonix, we believe that ground-breaking science only creates value when it is translated into a deployable, real-world solution. Over the past twelve months, our focus has shifted from the theoretical—identifying the "delivery gap" in retinal care—to the physical engineering of a device capable of closing it. We are proud to announce that we have successfully moved beyond the "proof of concept" phase and are now entering advanced prototype development. Here is a look

The field of retinal phototherapy is rapidly evolving, offering new hope for patients suffering from various retinal diseases. As clinicians, staying updated on these advancements is crucial for providing the best care possible. This blog post will explore the latest innovations in retinal phototherapy, their implications for clinical practice, and how they can enhance patient outcomes. Understanding Retinal Phototherapy Retinal phototherapy involves the use of light to treat

In a world where eye conditions are becoming increasingly prevalent, innovative solutions are essential. BioPhotonix stands at the forefront of this revolution, offering groundbreaking treatments that promise to change the way we approach eye health. With advancements in technology and a commitment to research, BioPhotonix is not just treating symptoms but addressing the root causes of various eye conditions. Understanding Eye Conditions Eye conditions can range from mild irr